Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
about
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitisRosiglitazone for type 2 diabetes mellitusDrugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitisCirculating liver-specific miR-122 as a novel potential biomarker for diagnosis of cholestatic liver injuryRole of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver diseaseCurrent therapeutic options in type 2 diabetes mellitus: a practical approachPeroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study.Developmental programming: insulin sensitizer treatment improves reproductive function in prenatal testosterone-treated female sheepCounseling patients with type 2 diabetes and insulin resistance in the outpatient setting.Evaluation of the immune response to pneumococcal capsular polysaccharides.The rational use of potentially hepatotoxic medications in patients with underlying liver disease.PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study.Pioglitazone in the treatment of type 2 diabetes: safety and efficacy reviewNeuroinflammation: a potential therapeutic target.Recent findings concerning thiazolidinediones in the treatment of diabetes.Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes.Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and managementThe Cause-and-Effect Relationship Between Type 2 Diabetes Mellitus and Clinically Overt Cryptogenic Cirrhosis: A Matter That Must Be Seriously Revised.Association of Diabetic Nephropathy and Liver Disorders.In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.Examining the safety of PPAR agonists - current trends and future prospects.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.The TZD insulin sensitizer clue provides a new route into diabetes drug discovery.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Prevalence of abnormal serum liver enzymes in patients with type 2 diabetes mellitus: a cross-sectional study from China.Late-onset rosiglitazone-associated acute liver failure in a patient with Hodgkin's lymphoma.Effects of PPARg agonist pioglitazone on rat hepatic fibrosis.Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes.Glycogen hepatopathy in a 13-year-old male with type 1 diabetes.Glycogenic Hepatopathy in Type 1 Diabetes Mellitus.Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes.Effect of curcumin on glucose and lipid metabolism, FFAs and TNF-α in serum of type 2 diabetes mellitus rat models.
P2860
Q24197984-7B51B9FC-8575-47D3-B88C-52186C1E99DCQ24243875-ED5983FD-32A7-4927-AC7F-067287B98440Q24246447-12104F00-961B-46B4-B32E-77064E6114CDQ28533876-5C6CF357-FB78-4F86-9830-4EB6D089AAA1Q33607697-CF3BFB8E-F7F0-4A36-9B84-52024BCAD11CQ33723387-3AA45770-F65B-4F5F-956C-7A28D38BE179Q33772312-AB725392-CC60-4DA0-A316-6447C691451AQ34132558-7A9AD416-24CC-4CD0-9132-F4F426A99FF1Q35044470-D4CEACD9-8864-4982-86F3-4900B5DFE24CQ35167055-71128BD8-BDDE-449B-A557-899DBA434AE1Q35194515-83D65570-A40F-40B5-A591-DCBFB49CEAC2Q36114026-33851113-52A0-43D1-92AA-F2A094B6FB11Q36139056-02DC37EB-79AB-47E3-AECB-AB66CC352ED7Q36268282-3AF8CCA1-2021-40E6-B88A-13C7B660D103Q36407304-0258B82B-7A15-4F2A-92C0-B2F4092D02ECQ36577073-22BA42B4-C9FC-4F39-A414-47A46D5D25F1Q36847318-46771F57-5A41-4A24-B077-19A5874331C6Q37122216-EEFA1B71-B75D-4D80-95C7-7696E331C4CBQ37387546-79AEE78D-E553-49AB-8F9C-B9DAB5FE4B92Q37435361-74F94A97-DC0F-4B58-917B-FA4DDC7C98DBQ37577126-0777CE93-A81C-497E-831E-E306293F073CQ38058381-73293269-D1A4-44B3-AF75-00BDBD3542E2Q38199526-F9830578-3388-43ED-B519-379A2CFD330BQ38606170-D8204EFD-E53A-4C4E-8D39-19C161C99397Q38610829-8F4950D6-826B-45EE-AB4A-5B982F66C7FAQ38641190-9EA77121-3273-41AC-92EA-0187FD053115Q39343214-24AC9D8B-2743-45C7-B92C-61D12A051625Q40422366-0B0B828B-50B3-4B62-9DA1-396FA882016DQ41908629-7142A3B2-CF2A-4CCD-9291-BF668B0795B3Q41931381-2E18E9CF-9E3A-4705-B83A-97D40277C871Q42101374-AEA61103-D331-48A0-9819-B65CD30B482FQ42758047-DBAA2A4C-295C-4772-83A6-7BD822F20A4BQ45402744-945E53BE-92E7-40CB-B7D6-44A084468DD2Q51002624-7847F0A1-F3B7-46F8-AA36-7CFC06A0C2E9Q51245000-25B35352-5FCE-44AE-8299-5A51DE4E542A
P2860
Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Evaluation of liver function i ...... not cause hepatic dysfunction.
@en
Evaluation of liver function i ...... not cause hepatic dysfunction.
@nl
type
label
Evaluation of liver function i ...... not cause hepatic dysfunction.
@en
Evaluation of liver function i ...... not cause hepatic dysfunction.
@nl
prefLabel
Evaluation of liver function i ...... not cause hepatic dysfunction.
@en
Evaluation of liver function i ...... not cause hepatic dysfunction.
@nl
P2093
P356
P1433
P1476
Evaluation of liver function i ...... not cause hepatic dysfunction.
@en
P2093
Harold E Lebovitz
Margaret Kreider
Martin I Freed
P304
P356
10.2337/DIACARE.25.5.815
P407
P577
2002-05-01T00:00:00Z